1 Title:

- 2 Rapid and modular workflows for same-day sequencing-based detection of bloodstream
- 3 infections and antimicrobial resistance determinants

4 Authors:

- 5 Mohammad Saiful Islam Sajib¹, Katarina Oravcova¹, Kirstyn Brunker^{1,2}, Paul Everest¹, Manuel
- 6 Fuentes¹, Catherine Wilson³, Michael E. Murphy^{3,4}, Taya Forde¹

7 Affiliations:

- 8 ¹School of Biodiversity, One Health & Veterinary Medicine, University of Glasgow, Glasgow,
- 9 United Kingdom
- 10 ²MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
- 11 ³Department of Microbiology, NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, New
- 12 Lister Building, Alexandra Parade, Glasgow, UK
- 13 ⁴School of Medicine, Dentistry & Nursing, College of Medical, Veterinary & Life Sciences,
- 14 Wolfson Medical School Building, University of Glasgow, Glasgow, UK

15 Keywords:

- 16 rapid diagnosis, selective host depletion, chemical host depletion, metagenomic next
- 17 generation sequencing, Oxford Nanopore technologies, selective sequencing, adaptive
- 18 sampling, bloodstream infection, antimicrobial resistance
- 19

15

20

- 21
- 22
- 23

. .

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract:

Background: Bloodstream infections (BSI) are a major global health concern, and existing
diagnostic methods are too slow to guide targeted antibiotic therapy for critically ill patients,
risking poor clinical outcomes. Rapid metagenomic-sequencing (mNGS) can facilitate swift
pathogen and antimicrobial resistance (AMR) detection, but identification is challenged by
significant host versus bacterial DNA in blood. To accelerate microbiological diagnosis, we
developed M-15, a rapid and modular mNGS-based host DNA depletion workflow, validated
with suspected BSI blood-culture samples and rapid culture-enriched spiked blood.

34 Methods: To assess chemical host DNA depletion (CHDD) efficiency, M-15 was benchmarked 35 with five commercial/published protocols. Later, M-15 was combined with rapid mNGS with/without adaptive sampling (AS) and tested on clinical blood-culture samples (n=33) from 36 suspected BSI cases identified on BACT/ALERT VIRTUO (30 flagged positive, three remained 37 negative). To determine whether it is possible to utilise M-15 mNGS prior to blood-culture 38 flagging positive, a rapid enrichment method was tested starting with 1-10 colony forming 39 units of the top 15 bacterial species causing BSI spiked into BACTEC medium enriched with 10 40 mL sheep blood. 41

Results: All six chemical depletion protocols reduced host DNA by 2.5x10^o to 4.1x10⁶-fold,
with the in-house M-15 protocol performing best, while adaptive sampling depleted host >5fold. With BACT/ALERT specimens, M-15 mNGS accurately identified 3/3 negative, 28/28
mono-bacterial, and 2/4 multi-bacterial species. With rapid culture-enrichment and M-15
mNGS, <18% DNA was classified as host and all bacterial species tested (n=10) were correctly
identified. M-15 mNGS accurately predicted phenotypic AMR/susceptibility for 90.3%
(232/257) of drug/bacteria combinations from BACT/ALERT positive samples.

49 Conclusions: This study demonstrates that M-15 mNGS can facilitate species and AMR gene
50 detection within 5-7 hours of BACT/ALERT positivity. Including 8-hour culture enrichment,
51 microbiological and AMR confirmation is possible within 13-15 hours of sample collection.
52 Thus, the M-15 mNGS workflow has the potential to improve patient outcomes in BSI.

54 Background

55 Bloodstream infection (BSI) is one of the leading causes of death worldwide, with 2.9 million cases each year [1]. Rapid identification of the causative bacterial pathogens and their 56 57 antimicrobial resistance (AMR) profiles is crucial for guiding more effective treatment and 58 better patient outcomes, especially for critically ill patients such as those who develop sepsis [2]. Blood culture, the gold standard diagnostic method, often takes 48-72 hours, which is too 59 slow to guide targeted antibiotic therapy. This necessitates the prescription of empirical 60 61 antibiotics, which may fail to cover the resistance profile of the causative pathogen and risk poor clinical outcomes [3]. Also, the use of broad-spectrum antibiotics to limit disease 62 progression may disrupt beneficial gut microbiota and contribute to the development of 63 64 multidrug-resistant bacteria often associated with healthcare infections, further limiting the 65 reserve of critically important antimicrobial agents [4]. Thus, there is an urgent need for rapid diagnostic tools to better inform antibiotic regimens at the early stages of BSI. 66 67 Certain applications of metagenomic next-generation sequencing (mNGS) could be used to rapidly identify bacterial species and AMR determinants, and therefore have the potential to 68 69 accelerate BSI diagnosis [5]. However, the proportion of host DNA in blood compared to that 70 of bacteria makes it challenging to directly sequence and generate adequate reads from the

71 pathogen to accurately identify species and AMR in a cost-effective manner and within a

72 clinically relevant timeframe. To address this issue, we developed a rapid mNGS-based

chemical host DNA depletion (CHDD) protocol, named M-15, and compared its performance

with two commercial kits (C1-2) and three published methods (P1-3) [6-8]. Next, M-15 mNGS

75 was validated with and without nanopore adaptive sampling using both culture (BACT/ALERT

an automated blood culture system) positive and negative enriched blood samples collected

77 from patients with suspected BSI. Finally, M-15 was combined and tested with a rapid (8-

78 hour) culture (BACT/ALERT) enrichment step to reduce turnaround time and enable same-day

79 microbiological diagnosis of bloodstream infections.

80 Methods

81 Bacterial strains and host matrix

Defibrinated sheep blood (E&O Laboratories, UK) and EDTA-treated whole blood from healthy
human volunteers were used as model host environment matrix. The list of clinical and/or

84 American Type Culture Collection (ATCC) strains tested/used in this study can be found in Tab.

85 1, S1, S2 and S3.

86 Primers, probes, and amplification parameters

87 To assess the depletion efficiency of the protocols, universal 16S rRNA, 18S rRNA and

88 bacterial species-specific primers and probes were utilised [9-12]. The total volume of

89 individual qPCR reactions was 20 μL, with 2x Rotor-Gene Multiplex PCR master mix (Qiagen,

90 Hilden, Germany) and 2 μL DNA template. qPCR reactions were performed on a Rotor-Gene Q

91 real-time cycler for up to 40 cycles (Qiagen, Hilden, Germany). The primer/probe sequences,

92 concentrations and PCR cycling parameters are provided in Tab. S4.

93 Benchmarking host depletion kits and protocols

94 A chemical host DNA depletion protocol, named M-15, was developed in this study (Fig. 1,

95 Supplement Protocol: M-15 mNGS) and benchmarked alongside two commercial [Zymo-

96 HostZERO (named C1; Zymo Research, CA, USA), MolYsis-Complete5 (C2; Molzym GmbH &


97 Co, Bremen, Germany)] and three published host depletion protocols P1 [6], P2 [8], and P3

98 [7].

To determine host depletion efficiency and analytical sensitivity of the workflows, serially 99 100 diluted (100 to 105 CFU/mL) exponential growth phase cells of Escherichia coli (ATCC 25922), 101 Staphylococcus aureus (ATCC 25923), and Pseudomonas aeruginosa (ATCC 27853) strains 102 were spiked in 400 μ L sterile whole blood (human and sheep) and processed to deplete host 103 cells/DNA with all the six protocols. Following host depletion with P1, P2, P3 and M-15, DNA extraction was performed using QIAamp UCP Pathogen Mini Kit (Qiagen, Hilden, Germany) 104 with the recommended homogenisation step by bead beating (Pathogen Lysis Tubes L, 105 Qiagen, Hilden, Germany). For protocols C1 and C2, DNA extraction was performed using the 106 107 reagents supplied with the kits. Total DNA was extracted from the same spiked blood samples 108 without host depletion similarly as unenriched (non-CHDD) controls. Extracted DNA was 109 tested using qPCR with the 16S rRNA, 18S rRNA, and species-specific primers/probes 110 described above.

In addition, a subset of the simulated M-15 CHDD samples, containing 10⁴ to 10¹ CFU/mL
 blood was extracted, amplified and barcoded for sequencing using ONT Rapid PCR barcoding

- 113 kit (SQK-RPB004; Oxford Nanopore technologies, Oxford, UK) and sequenced on MinION
- 114 R9.4.1 flow cells. Live GPU basecalling was performed in high accuracy mode
- 115 (dna_r9.4.1_450bps_hac) and passed Fastq reads were analysed using Chan Zuckerberg
- 116 infectious diseases (CZ ID) (v0.7; <u>https://czid.org/</u>) Nanopore workflow (last accessed:
- **117** 07/08/2024) [13].



118

Fig. 1: Schematic diagram depicting major steps involved in M-15 CHDD and mNGS workflow. Both
BACTEC flagged positive and rapid enriched (8-hour), blood culture samples can be used as input. M15 CHDD is the first step where host DNA is selectively depleted with saponin and DNase I treatment.
Host depleted materal is then subjected to alkaline lysis and whole genome amplification with REPLI-g
single cell kit. Amplified product is then debranced using T7 Endonuclease I and sequencing is
performed with rapid barcoding (mid-low yield) or native barcoding (high-yield) kit.

125 Determining the contribution of host depletion on bacterial cell loss/viability

- 126 Bacterial cell loss and/or viability following host depletion was determined using *E. coli, S.*
- 127 aureus, and P. aeruginosa ATCC strains. Approximately 30 and 3 CFU of the exponential phase
- 128 cells were spiked in 400 μL sterile whole blood, and the samples were processed to deplete
- host DNA with three top performing protocols C1, C2, P1, and M-15. Host depleted samples
- 130 were resuspended in PBS and plated on nutrient and blood agar media to estimate bacterial
- 131 concentrations using the method described by Miles & Misra [14]. The same samples were

132 plated directly without host depletion as controls. All the inoculated plates were incubated

133 overnight at 37°C, and the number of visible colonies was recorded the next day.

134 Rapid M-15 mNGS workflow tested on culture enriched specimens

135 To determine the efficiency of M-15 mNGS protocol on culture enriched samples, six culture 136 enriched suspected BSI samples were tested initially. Three samples flagged positive on BACT/ALERT (bioMérieux, Marcy-l'Étoile, France) and the remaining three were reported to 137 138 be culture negative. The same samples were processed directly without M-15 as no depletion controls. To minimise hands on time, rapid alkaline cell lysis was performed using 4 μ L direct 139 or host depleted samples resuspended in 1 mL PBS using REPLI-g single cell kit (Qiagen, 140 Hilden, Germany). Multiple displacement amplification (MDA) was performed with the same 141 142 kit for 60 minutes according to the manufacturer's recommendation. Amplified MDA 143 products were then debranched for 10 minutes at 37° C using T7 endonuclease (New England 144 Biolabs, MA, United States) and subjected to 0.5x AMPure bead cleanup. Library was prepared using ONT Rapid barcoding kit (SQK-RBK004) with 400 ng amplified debranched 145 DNA product/sample as an input (Supplement Protocol: M-15 mNGS + low-medium yield 146 protocol). The overall sample processing time of this pilot version of the workflow is 147 approximately 4 hours (processing 6-10 samples), including 80 minutes for host depletion, 20 148 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLI-g Single 149 150 Cell Kit, and 90 minutes for debranching, cleanup, library preparation and flow cell loading. 151 To assess the efficiency of adaptive sampling (AS) with or without CHDD with M-15, rapid

adapter ligated pooled libraries (six CHDD and six no CHDD) were loaded on a MinION R9.4.1

153 flow cell and the total number of channels (N= 512) available for sequencing were divided

154 into two parts from the advanced option menu on the MinKNOW graphical user interface.

155 Channels 1 to 256 were chosen for human DNA depletion using T2T-CHM13v2.0 as reference

156 [15] and channels 257-512 for no-adaptive sampling control.

157 High yield M-15 mNGS workflow validated with culture-positive suspected BSI specimens

158 An additional 27 blood culture positive samples were tested using the optimised workflow for

159 improved sequencing yield. Chemical host depletion, DNA extraction, MDA (60 minutes) and

160 debranching were performed similarly to the pilot protocol. Only this time, library preparation

161 was performed using Ligation Sequencing Kit (SQK-LSK109) with native barcodes (EXP-

NBD104) with 400 ng amplified debranched DNA product/sample as an input (Supplement 162 Protocol: M-15 mNGS + high yield protocol). The overall sample processing time of this 163 optimised workflow takes less than 6 hours (with 6-10 samples) including 80 minutes of 164 165 CHDD, 20 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLIg Single Cell Kit, and about 180 minutes for debranching, library preparation and loading. 166 167 To identify bacterial species, CZ ID pipeline was utilised as mentioned above with a 20% abundance cutoff (200,000 Base Per Million; BPM for CZ ID). Host-filtered contigs remaining 168 169 after the 20% abundance cutoff were analysed to identify AMR determinants with ResFinder 4.5.0 [16] using the default options. In addition, host filtered fastq reads remaining after 20% 170 abundance cutoff were mapped against bacterial reference sequences using minimap2[17] to 171 172 estimate the breadth of coverage and sequencing depth. To determine the minimum sequencing yield required to identify bacterial species and AMR determinants, 100 Mbp, 50 173 Mbp, 40 Mbp, 30 Mbp, 20 Mbp, and 10 Mbp raw fastq reads were randomly subsampled 174

using rasusa [18] and processed similarly with CZ ID and ResFinder.

176 Rapid culture enrichment to accelerate microbiological diagnosis

177 A shorter culture enrichment method was tested with 16 ATCC/clinical isolates representing eight Gram negative and seven Gram positive bacterial species. Approximately 1-10 CFU of 178 179 actively growing (log phase) bacterial cells were spiked in BD BACTEC[™] Standard Blood Culture media (Becton, Dickinson and Company, NJ, USA) supplemented with 10 mL sterile 180 181 whole blood (sheep), and then subjected to incubation. Culture bottles were taken out at 2hour intervals over a span of 10 hours and subsequently plated on nutrient and blood agar 182 media using the Miles & Misra method. [14] All the plates were incubated at 37°C overnight 183 and the number of visible colonies was recorded the next day. One mL culture-enriched 184 samples were preserved at-80°C during each sampling session to be tested later. Finally, a 185 subset (10/16) of the 8-hour culture-enriched samples (5 Gram-positive and 5 Gram-negative 186 species) were chosen and processed with the high yield M-15 mNGS protocol (Supplement 187 188 Protocol: M-15 mNGS + high yield protocol). Species, host: pathogen ratio, antimicrobial resistance genes and minimum DNA yield per sample for identification were determined 189 using the same pipelines and cutoffs mentioned above. 190

192 Conventional tests for detecting species, AMR, and predicting AMR with sequencing

- 193 In the routine diagnostic microbiology laboratory, 5-10 mL EDTA treated blood samples
- 194 collected from suspected individuals were incubated in the BACT/ALERT system for up to 5
- days. Samples that flagged positive were taken out and inoculated onto appropriate agars,
- 196 and organisms grown identified using MALDI-TOF mass spectrometry (Bruker Corporation,
- 197 MA, USA). Phenotypic antimicrobial sensitivity was determined using disc diffusion as
- 198 described by European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline
- 199 [19] or automated systems, e.g. Vitek2 (bioMérieux, Marcy-l'Étoile, France).
- 200 To compare routine phenotypic sensitivity and genotypic antimicrobial susceptibility results,
- AST results for the BACT/ALERT positive BSI samples were compared to ResFinder 4.5.0
- 202 phenotype table results. Because ResFinder provides AMR predictions for 92 antimicrobial
- agents from 21 antibiotic classes, but only predicts resistance or susceptibility (not
- 204 Intermediate results), only the phenotypic results common between the two (culture and
- sequencing) and classified as resistant or susceptible were compared. For rapid culture
- 206 enriched spiked blood samples, for which AST results were not available, WGS (where
- available) and M-15 mNGS data of the ten ATCC/clinical isolates were compared similarly
- using ResFinder 4.5.0 phenotype table. Categorical agreement, major error and very majorerror were calculated using the following formula [20]:

210 $Categorical agreement = \frac{TR + TS}{TR + TS + FR + FS}$

211

212 Major error =
$$\frac{FR}{FR + TS}$$

213

214 Very major error
$$=$$
 $\frac{FS}{FS + TR}$

- 215 Where: TR = True resistant, TS = True susceptible, FR = False resistant, FS = False susceptible,
- and where phenotypic AST is taken as the gold standard.
- 217

219 Statistical analysis

- 220 R studio 2023.12.1 with R base version 4.3.3 were used in combination with readxl, dplyr,
- reshape2, ggplot2, and gridExtra packages for performing data cleanup, formatting, analysis
- and generating graphs.
- 223 Results

224 Chemical depletion protocols remove unwanted host with high efficiency

- **225** Protocols M-15 and P1 removed 4.1×10^6 (Quantification cycle Δ Ct-20.52) and 5.5×10^5 fold (Δ Ct-17.45)
- host DNA, respectively, from the whole blood samples spiked with Escherichia coli, Staphylococcus
- aureus, or Pseudomonas aeruginosa ATCC strains, with depletion efficiency over 99.99%. Commercial
- 228 kit C1 removed 99.82% (5.87×10² fold) host, and C2, 97.93% (4.84×10¹ fold). Approximately 81.09%
- and 59.19% host were removed with the protocols P2 and P3, respectively (**Tab. 1**). Between 5.58%
- 230 (P3) and 51.63% (M-15) bacterial DNA were removed during host depletion with the six
- 231 kits/protocols. Protocols with higher depletion efficiencies also exhibited increased bacterial
- 232 DNA loss (Tab. 1).
- 233 Protocol C2 exhibited a strong negative bias towards *P. aeruginosa*, as >99% (ΔCt -10.27) loss
- was observed, possibly due to the detrimental effect of buffer CM (a selective host cell lysis
- buffer provided in the kit) on this bacterial species during the host lysis steps. In a recent
- study, where blood culture positive samples were processed with protocol C2 to deplete host
- and enable rapid sequencing-based species and AMR identification [20] sequencing results
- also indicated suboptimal accuracy of C2 mNGS for *P. aeruginosa* compared to other bacterial
- 239 species, possibly indicating similar lysis bias [20].

240 Tab. 1: Host depletion efficiency and bacterial DNA loss observed with in-house chemical host DNA

depletion method, M-15, compared with two commercial kits (C1-2) and 3 published protocols (P1-3). 241

Organism	Methods/Kits	Ct (SD) No chemical depletion	Ct (SD) Chemical depletion	ΔCt	Fold Reduction	DNA Removal (%)	
Host depletion	efficiency						
Ovis aries	M-15 (this study)	16.24 (0.79)	36.76 (1.82)	-20.5	4.1×10 ⁶	99.99998%	
Ovis aries	P1 [6]	16.24 (0.79)	9) 33.69 (0.99)		5.5×10 ⁵	99.99982%	
Ovis aries	Zymo HostZero (C1)	20.30 (0.58)	29.74 (2.10)	-9.43	5.9×10 ²	99.82966%	
Ovis aries	Molysis Complete 5 (C2)	20.51 (0.64)	25.73 (1.08)	-5.2	4.8×10 ¹	97.93324%	
Ovis aries	P2 [7]	18.97 (0.49)	21.15 (0.53)	-2.2	5.3×10°	81.09315%	
Ovis aries	P3 [8]	18.97 (0.49)	20.15 (0.51)	-1.2	2.5×10°	59.19500%	
Bacterial loss							
E. coli	M-15 (this study)	23.69 (1.04)	23.91 (0.47)	-0.22	1.3×10°	23.87932%	
E. coli	P1 [6]	23.94 (0.43)	22.41 (0.22)	1.5	0.35	0.00%	
E. coli	Zymo HostZero (C1)	24.57 (0.34)	25.34 (0.65)	-0.8 1.6×10 ⁰		37.93000%	
E. coli	Molysis Complete 5 (C2)	23.73 (0.67)	23.27 (0.55)	0.5	0.74	0.00%	
E. coli	P2 [7]	22.18 (0.28)	22.84 (0.73)	-0.7	1.5×10°	31.14783%	
E. coli	P3 [8]	22.18 (0.28)	21.39 (0.24)	0.8	0.58	0.00%	
P. aeruginosa	M-15 (this study)	23.09 (0.46)	24.26 (0.66)	-1.2	2.1×10 ⁰	53.08692%	
P. aeruginosa	P1[6]	21.84 (0.32)	23.53 (0.27)	-1.7	3.3×10°	69.37233%	
P. aeruginosa	Zymo HostZero (C1)	25.98 (0.23)	26.70 (0.17)	26.70 (0.17) -0.7		39.94829%	
P. aeruginosa	Molysis Complete 5 (C2)	25.03 (0.38)	35.31 (1.79)	-10.3	6.8×10 ²	99.85400%	
P. aeruginosa	eruginosa P2 [7] 23.62 (0.46) 24.09 (0.23)		-0.5	1.4×10°	30.04768%		
P. aeruginosa	P3 [8]	P3 [8] 23.56 (0.44) 23.43 (0.44) 0.1 0.92		0.92	0.00%		
S. aureus	M-15 (this study)	M-15 (this study) 20.59 (1.15)		-1.9	4.5×10 ⁰	77.91082%	
S. aureus	P1 [6]	21.94 (1.06)	22.74 (0.40)	-0.8	2.0×10 ⁰	50.21738%	
S. aureus	Zymo HostZero (C1)	26.76 (0.62)	26.07 (0.27)	0.7	0.66	0.00%	
S. aureus	S. aureus Molysis Complete 5 (C2) 22.78 (0.31)		23.33 (0.61)	-0.6	-0.6 1.4×10 ⁰ 2		
S. aureus	P2 [7]	22.78 (0.31)	23.46 (0.23)	-0.7	1.6×10 ⁰	38.07282%	
S. aureus	P3 [8]	22.78 (0.31)	23.04 (0.26)	-0.3	1.2×10 ⁰	16.75203%	

SD: Standard deviation, Ct: Cycle threshold, Δ Ct: Difference in quantification cycle 242

CHDD protocols perform poorly with samples containing low bacterial concentrations 243

Although the host depletion efficiency of some of the protocols, including M-15 was 244

245 encouraging, we observed some bacterial loss. Therefore, we aimed to evaluate their

applicability on blood samples with low bacterial concentrations (1 to 100 CFU/mL), as 246 typically seen in BSI cases [21]. For this, we selected the top performing protocols, M-15, P1, 247 248 C1 and C2, which exhibited the highest host depletion efficiency. For all three ATCC strains 249 tested (E. coli, S. aureus, P. aeruginosa), qPCR analytical sensitivity of protocols M-15, P1 and C1 was 10² CFU/mL. With protocol C2, qPCR was able to detect up to 10¹ CFU/mL *E. coli* and 250 S. aureus; however, like before, Ct values from P. aeruginosa spiked CHDD samples were 251 consistently very high (Ct >30) across all five *P. aeruginosa* concentrations (10^o to 10⁴ CFU/mL) 252 spiked in whole blood (Fig. 2A). 253

254 To understand which part (chemical wash or DNA extraction) of the CHDD protocols is 255 contributing to reduced recovery of bacterial DNA, we processed low abundant spiked samples 256 (<30 and <3 CFU/mL) with M-15, P1, C1 and C2 protocols and confirmed viability/recovery with culture. Viable plate counts following CHDD showed protocols C1 retained 92%, M-15 76% and 257 258 P1 62% of bacteria of the low initial counts of <30 cells spiked in blood (Fig. 2B). With even 259 lower concentration (<3 cells), the overall bacterial recovery rate with protocols C1, M-15, and P1 were 72%, 43% and 13% respectively compared to the no CHDD controls (Fig. 2B). No viable 260 bacteria were recovered using protocol C2 for any of the bacterial species or samples tested; 261 again, possibly indicating buffer CM's effect on their growth or viability, although P. aeruginosa 262 263 was the only species (specifically ATCC 27853) tested in this study that displayed suboptimal 264 performance with downstream molecular assays (Fig. 2B).

265 In order to estimate the proportions of expected bacterial DNA (i.e., bacterial species spiked 266 initially) versus host and others (unclassified and other species), a subset of simulated M-15 CHDD samples (highest host depletion efficiency; 4.1×10⁶ fold), having 10⁴ to 10¹ E. coli CFU/mL 267 were sequenced. While the host: bacteria DNA ratio might differ between bacterial species 268 269 due to the difference in their genome size, this would facilitate estimating the lowest bacterial 270 concentration (CFU/mL) that would most likely provide consistent results with downstream 271 molecular applications, especially sequencing. The proportion of expected bacterial (E. coli that 272 were initially spiked) DNA sequence yield (mega base pairs; Mbp) in M-15 CHDD samples were 53.4% and 9.7% of total DNA for samples containing 10^4 and 10^3 CFU/mL bacteria respectively. 273 For low abundant samples, bacteria represented only 1.1% (10² CFU/mL) and 0.2% (10¹ 274 275 CFU/mL) of total DNA yield following >99.99% host removal with M-15 (Fig. 2C). Proportion of DNA sequence yield from expected bacterial species compared to the host remained 276

unchanged throughout the sequencing run regardless of bacterial concentration spiked or DNA
ratio (Fig. 2C). The suboptimal host: pathogen ratio in low abundant blood samples meant that
sequencing-based assays may not yet provide satisfactory results even with CHDD, unless an
additional enrichment/depletion step is included pre/post DNA extraction to further improve
bacterial proportions, and a more robust and sensitive DNA extraction method is benchmarked
and validated.



283

Fig. 2: Overall performance of M-15 versus published/commercial protocols (A) qPCR Ct values 284 285 (median and standard deviation) of different concentrations (10^4 to 10^0 CFU/mL - see legend) of 286 three ATCC strains (Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus) spiked in 287 whole blood and processed with top chemical host DNA depletion (CHDD) kits/protocols (P1, M-15, 288 C1, and, C2) performing the best in terms of host DNA depletion. (B) Number of viable cells recovered from blood samples spiked with <30 and <3 CFU of the three ATCC strains following CHDD with P1, M-289 290 15, C1, and, C2, compared to the no CHDD/PBS control. (C) Proportion of expected bacteria initially 291 spiked in blood for M-15 CHDD, compared to host (sheep) DNA, other bacterial species (different from 292 the three species spiked), and unclassified reads, over 16 hours of MinION sequencing. The four facets 293 are showing simulated/spiked bacterial concentration ranging from 10⁴ to 10¹ CFU/mL of sheep blood.

294 M-15 mNGS and adaptive sampling significantly improve bacterial proportions

- 295 Due to suboptimal performance of M-15 mNGS observed with low bacterial concentrations
- 296 directly in blood samples, three BACT/ALERT positive (BCP01-BCP03) and three negative


(BCN01-BCN03) culture enriched samples from suspected BSI cases were initially tested witha rapid version of M-15 CHDD protocol (Fig. 1).

Length of the sequencing reads varied significantly among organisms, with expected bacterial
species (species that were identified with culture-based methods) having the highest median
read length (1,957 bp); this was 8.15x longer than the unclassified reads (240 bp), 3.52x
longer than human reads (552 bp) and 1.7x longer than other bacterial reads (mixed bacterial
species not expected from the sample; 1,145 bp) (Fig. 3A). The read length difference
between host and bacteria could be the result of CHDD, as host DNA was digested with
DNase I following selective lysis.

- **306** Overall yield in the adaptive sampling (AS) channels (1-256) was 1.86x lower (550.33 Mbp AS
- 307 vs 1023.72 Mbp no-AS) than no-AS (channels 257-512), although the total number of reads
- 308 for AS and no-AS samples was almost the same, with 345,085 and 334,054 reads,
- 309 respectively. Median read length for AS channels was 3.2x shorter than the no-AS, and host
- constituted >90% of the reads that were smaller than 1kb in AS channels (Fig. 3B). This
- 311 illustrates that AS influenced the length of sequenced fragments as a result of its limited
- ability to deplete shorter host reads (≤ 1 Kbp), which were highly abundant in the directly
- **313** extracted no-CHDD samples.

Samples processed with M-15 CHDD had 1.14 ×10³ times less human DNA compared to the
no CHDD controls (based on sequencing yield in Mbp; Fig. 3D). Samples sequenced using AS
had 5.52-fold less human DNA compared to the controls; however, no bacterial enrichment
was observed (Fig. 3C, 3D). This highlights the importance of host depletion even in positively
flagged culture-enriched specimens, as it may lead to lower sequencing cost per sample, and

- 319 more importantly, reduce the sequencing time required to reach a desired yield for
- 320 determining the bacterial species responsible for the BSI.



321

322 Fig. 3: Host depletion efficiency of M-15 mNGS and adaptive sampling (AS), versus no chemical 323 host DNA depletion (CHDD) and no AS, tested with patient samples (A) Violin plot showing size 324 distribution of sequencing reads aligned to expected bacterial species, host (human), other bacterial 325 species, and reads for which there were no matches within the blast Nr/Nt database. (B) Histogram 326 highlighting the number of raw sequencings reads from expected bacteria, host, others (other 327 bacteria or unclassified). Coloured facets subdividing the raw reads further to distinguish read length 328 variation by AS, no AS and CHDD and no CHDD. (C) Overall sequencing yield of CHDD and no-CHDD samples sequenced, comparing AS and no-AS. Stacked coloured bars highlight the proportion of DNA 329 330 aligned to host, bacteria and others/unclassified species (see legend). Blood culture positive (BCP) 331 samples are shown in red text, while blood culture negative (BCN) samples are shown in black. (D) 332 Depletion efficiency (fold difference, FD) in DNA yield (Mbp) of sequences from host with CHDD and 333 AS compared to no-CHDD and no-AS.

M-15 mNGS accurately predicts mono-bacterial species in BACT/ALERT positive samples 334


- 335 Because suboptimal sequencing yield was observed when debranched M-15 CHDD Multiple 336 Displacement Amplification (MDA) samples were initially processed (rapid M-15) using the
- rapid barcoding kit (Fig. 1), it was decided to utilise the Ligation sequencing kit with native 337

barcodes (Fig. 1). Additional 27 culture (BACT/ALERT) positive BSI blood samples wereprocessed with the high-yield M-15 mNGS protocol.

Overall, blood-culture positive (BCP) samples subjected to CHDD had 152.4x higher DNA 340 341 concentration compared to culture negative (BCN) samples (BCP CHDD 509.02 ng/ μ L versus 342 BCN CHDD 3.34 ng/ μ L, as measured using Qubit) after 60 minutes MDA (Fig. 4A, Tab. S1). 343 However, directly extracted and amplified blood culture negative samples yielded 753 ng/ μ L DNA on average following 1-hour MDA with REPLI-g kit (Tab. S1). Four bacterial species with 344 345 high GC content, Brevibacterium luteocum (GC 67.8%), Micrococcus luteus (GC 74.0%), Stenotrophomonas maltophilia (GC 66.7%) and Achromobacter xylosoxidans (GC 64.0%) 346 yielded low DNA (15.7x less than other species), with an average of 32.23 ng/ μ L after 1-hour 347 348 MDA; however, this was still 9.64x higher than BCN samples following CHDD (Tab. S1). The 349 potential reason behind low yield in species with high GC%could involve stable secondary structure or denaturation difficulties as highlighted in some studies [22, 23]. 350 With CZ ID, using a cutoff of 20% abundance (200,000 Bases Per Million: BPM) successfully 351 removed all bacterial species identified except those detected using culture-based methods. 352 Using this cutoff, sequencing correctly identified 28/28 mono-bacterial species, 3/3 negative 353 samples and 2/4 multi-bacterial species found in two samples (Fig. 4B, S1 A). 354 355 Initially, it was assumed that the two species (K. oxytoca and E. faecalis) in two mixed samples (BCP05, and BCP24) were missed due to bacterial cell lysis during CHDD (Fig. 4B). However, 356 357 some of the mono-bacterial samples tested in this study contained the same bacterial 358 genera/species and no negative bias was observed with sequencing following CHDD. Also, all the CHDD flagged positive samples (n=30, species=17) were cultured overnight to confirm 359 viability, and only one (*M. luteus*) showed visible growth impairment on agar plates (**Tab. S1**). 360 361 Therefore, it is likely that these two organisms were missed with sequencing due to their relatively low abundance compared to the other species present in the sample. For one 362 sample (BCP15), Klebsiella pneumoniae was identified with culture but Klebsiella variicola 363 364 with mNGS; however, the species was later confirmed to be K. variicola with 16S rRNA 365 amplicon sequencing. Overall, expected bacterial species constituted 88.7% of total

366 sequencing yield versus human which represented only 0.46% total DNA (Fig. 4B).





368 369 Fig. 4: Species and antimicrobial resistance prediction accuracy of M-15 mNGS (A) DNA 370 concentration (ng/µL) of three blood culture negative (BCN01-BCN03) and 30 blood culture flagged 371 positive (BCP) samples, following M-15 chemical host DNA depletion (CHDD), and whole genome amplification with the REPLI-g kit. Quantification was performed with Qubit Broad Range dsDNA assay. 372 (B) Proportion of expected bacterial DNA (yellow bar chart; confirmed by culture) versus all other 373 374 reads following M-15 CHDD and MinION sequencing with native barcoding kit. BACT/ALERT positive 375 samples that have species-level agreement with culture have text labelled dark blue, those with genus-level agreement are purple, and those not detected by sequencing are labled red. (C) 376 377 Cumulative depth for eight Gram-positive and nine Gram-negative organisms from 30 BACT/ALERT positive blood culture samples following M-15 mNGS, with 100 Mbp sequencing yield per sample. (D) 378 379 Number and proportion of true positive, true negative, false positive and false negative AMR 380 predictions with M-15 mNGS compared to the standard culture-based AST prediction for 30 BACT/ALERT positive blood culture samples. (E) Number and proportion of ResFinder true positive, 381 382 true negative, false positive and false negative AMR predictions with M-15 mNGS by bacterial species

from the 30 BACT/ALERT positive blood culture samples tested in this study. (F) Number and
proportion of true/false AMR predictions with mNGS for the same culture-positive samples
categorised by antibiotics tested. Prediction of AMR profile with mNGS was done only using the
resistance and susceptibility results from antibiotics that were present in both phenotypic and
genotypic datasets (n=257).

388 To understand the breadth of coverage across the bacterial genomes with 100 Mbp sequencing yield per CHDD sample, 100 Mbp fastq reads subsampled with rasusa were 389 analysed. For every 100 Mbp DNA sequenced per sample, 96.76% and 99.48% coverage could 390 be achieved with at least 1x depth for the Gram-positive and Gram-negative organisms 391 tested, respectively. For 5x and 10x depth, Gram positive organisms had a mean genome 392 393 coverage of 87.89% and 78.29% and Gram-negatives 95.28% and 78.38%, respectively (Fig. 394 4C). For all the 30-blood culture positive samples tested (BCP01 to BCP30), >20% abundance cutoff accurately identified the present bacterial species with as low as 10 Mbp sequencing 395 yield per sample (Fig. S1 A). 396

397 Rapid culture enrichment can facilitate same-day microbiological identification

- 398 When a blood culture is flagged as positive, it contains approximately 10⁷ to 10⁹ bacterial
- 399 cells/mL of culture broth[24], which is more than the input concentration ($\geq 10^4$ CFU/mL)
- 400 required for the M-15 mNGS to work reliably, as observed during our initial experiments (Fig.
- 401 2C). This meant that a shorter culture enrichment step could further accelerate the
- 402 microbiological diagnosis, and M-15 mNGS could be utilised even before a sample flags
- 403 positive. However, given the variety of bacterial species involved in BSI and differences in their
- 404 growth rate, we aimed to understand the minimum incubation period required to reach that
- 405 threshold with a representative range of clinically important bacterial species (n=15).
- 406 Four of 15 bacterial species tested (*Streptococcus agalactiae, Acinetobacter baumanii,*
- 407 *Klebsiella pneumoniae* and *Escherichia coli*) reached 10⁴ CFU/mL, the optimal concentration
- 408 for M-15 mNGS, under 6 hours of culture enrichment (Fig. 5A). With 8-hour incubation,
- 409 12/15 species reached the desired threshold of 10⁴ CFU/mL. The remaining three species,
- 410 Staphylococcus aureus, Streptococcus pneumoniae and Pseudomonas aeruginosa, were
- 411 slightly lagging, reaching approximately 6.04x10³ CFU/mL on average with 8-hour enrichment.
- 412 All the species (15/15) tested reached/crossed the threshold under 10 hours of culture
- 413 enrichment (**Fig. 5A**).

414 To identify proportions of expected bacteria obtained using M-15 mNGS after 8-hour rapid culture enrichment, three sterile blood culture samples and a subset of 10 bacterial species (5 415 416 Gram positive and 5 Gram negative, including the three slow-growing species tested earlier) 417 were selected and processed with this approach (Fig. 5A, C). One potential costly drawback with the rapid enrichment approach could be the necessity to blindly sequence all blood 418 cultures if the positive and negative samples could not be differentiated prior to sequencing. 419 However, following CHDD and 60 minutes of MDA, the rapid culture-enriched spiked blood 420 samples (RESB, n=10) showed 28.16x higher dsDNA concentration (154.6 versus 5.49 ng/ μ L) 421 on average compared to sterile human blood enriched as negative controls (SBC, n=3), 422 423 providing a unique signature for the detection of positive samples prior to sequencing (Fig. 424 5B, Tab. S2).

425 Following sequencing, expected bacteria represented 89.4% of total DNA yield on average for

426 7 samples that reached 10⁴ CFU/mL under 8-hours versus 50.06% for the remaining 3

427 samples having relatively slow-growing species. All samples combined, 75.4% of the total DNA


428 yield matched with the bacterial species initially used for spiking and enrichment and 17.64%

429 with host species (Fig. 5C). Similar to BACT/ALERT positive samples, >20% abundance

430 threshold successfully identified 10/10 bacterial species sequenced to validate the rapid

431 enrichment protocol (Fig. 5C). Also, like before, as low as 10 Mbp yield (subsampled) was

432 sufficient to accurately identify bacterial species with the abovementioned cutoff (Fig. S1 B).



433

434 Fig. 5: Rapid culture enrichment: species covered, overall accuracy in species and antimicrobial

435 resistance prediction. (A) Time to reach 10⁴ colony forming units (CFU)/mL (green line; optimal 436 concentration for chemical host DNA depletion (CHDD) with culture-based bacterial enrichment prior 437 to M-15 CHDD and mNGS, tested with the top 15 bacterial species causing bloodstream infection. (B) DNA concentration $(ng/\mu L)$ of the three strerile culture-enriched blood (SBC01-SBC03) and ten rapid 438 439 (8-hours) culture enriched spiked blood samples, following M-15 CHDD, and whole genome 440 amplification with the REPLI-g kit. Quantification was performed with Qubit broad range assay. (C) 441 Proportion of expected bacteria (yellow; spiked initially) versus all other reads following M-15 CHDD 442 and MinION sequencing. Species, genus and non-agreements from rapid culture-enriched samples are 443 highlighted with the same colored labels as before. (D) Number and proportion of ResFinder true 444 positive, true negative, false positive and false negative AMR predictions with M-15 mNGS compared

445 to the whole genome sequencing (WGS) results of the same isolates/strains. MR: methicillin-resistant

446 In silico prediction of AMR is promising but requires improvement for clinical use

- 447 The accuracy of AMR prediction for the BACT/ALERT positive samples was determined
- comparing the ResFinder phenotype antibiotic data with the phenotypic culture-based 448
- antimicrobial susceptibility testing (AST) results (n= 257). For all 30 culture positive samples, 449
- mNGS exhibited 90.32% (232/257) categorical agreement overall, with 8.49% (18/212) major 450
- error and 15.55% (7/45) very major error (Fig. 4D). Among the 17 bacterial species, 451

452 discrepancies in resistance calls for *K. michiganensis* (5/18), *K. pneumoniae* (6/18), and *S.*

- 453 *aureus* (5/18) contributed to the highest number of major errors, and *E. coli* (2/07) and *S.*
- 454 *epidermidis* (2/07) towards very major error (Fig. 4E). Of 27 antibiotics for which results were
- 455 compared, very major error for ciprofloxacin was most common (3/7), possibly due to the
- 456 relatively low accuracy of ONT reads and the frequent association of resistance to
- 457 fluoroquinolones with mutations in quinolone resistance determining region (QRDR) of DNA
- 458 gyrase and topoisomerase encoding genes, as opposed to resistance encoding gene
- 459 presence/absence in other antibiotics.[25] Clindamycin (4/18) and piperacillin/tazobactam
- 460 (3/18) were the top two antibiotics exhibiting major errors (Fig. 4F).
- 461 Due to the smaller number of ATCC strains and clinical isolates (n =10) tested, and
- 462 unavailability of phenotypic AST data for a few clinical isolates, AMR predictions of M-15
- 463 mNGS with the rapid culture method were compared to whole genome sequencing (WGS) of
- 464 pure bacterial strains predicted AMR of the same strains/species using ResFinder (n = 920
- 465 predictions). Overall categorical agreement for M-15 mNGS versus WGS was 98.7% (908/920)
- 466 and mNGS exhibited 89.1% true susceptible, 9.6% true resistant, 1.3% false susceptible and
- 467 no false resistant predictions (Fig. 5D). *P. aeruginosa* was the only species for which
- 468 sequencing results did not match perfectly with its reference genome (12/92 predictions) and
- therefore was the only source of false susceptibility, possibly due to its high GC content
- 470 leading to inefficient/uneven DNA amplification with the REPLI-g kit (Tab. S2).
- 471 For both BACT/ALERT positive blood culture and rapid enriched spiked blood M-15 CHDD
- 472 blood, \geq 50 Mbp sequencing yield was sufficient to predict AST profiles, with the accuracy
- almost the same as having a sequencing yield of >100 Mbp per sample (Fig. S2, S3).

474 Discussion

Timely identification of pathogens and their antimicrobial resistance profile is crucial in BSI
because more targeted and effective antibiotic therapy can minimise the progression and
severity of the disease and therefore lead to improved patient outcomes. In addition,
reduced prescription of broad-spectrum antibiotics may help preserve their effectiveness,
limit the emergence of new antibiotic-resistant strains and protect the valuable microbiota
that plays an important role in maintaining overall nutrition and health [26]. Rapid
sequencing-based methods, especially in combination with selective chemical depletion

approaches, have the potential to reduce turnaround time and therefore lessen detrimental
outcomes. In working towards this goal, this study initially assessed the effectiveness of five
published and commercial, one in-house and one computation-based host depletion
strategies.

486 As a first step, we compared the effectiveness of an in-house host depletion method (M-15) with five published and commercial approaches, as well as a computation-based host 487 depletion strategy. The host depletion efficiency of most of the CHDD workflows was 488 489 outstanding (particularly for M-15 and P1). However, we also noticed a correlation between 490 depletion efficiency and loss of bacterial DNA with some protocols (e.g., C2) showing significant negative bias towards some species. For samples with low bacterial abundance, 491 the proportion of bacterial DNA was insignificant, \leq 1% of total DNA, even after M-15 CHDD, 492 which can remove >99.99% host DNA. However, bacteria represented >50% of total DNA 493 sequence yield for the CHDD samples containing $\geq 10^4$ CFU/mL bacteria. This meant additional 494 enrichment/depletion was necessary to get improved proportions of the sequencing yield 495 that is bacterial. As a simple and cost-effective alternative, we realised that a culture-based 496 497 enrichment step prior to CHDD and sequencing might improve DNA extraction 498 efficiency/robustness and proportion of bacteria in the sample simultaneously.

499 Therefore, we initially tested BACT/ALERT positive samples with two versions of M-15 mNGS 500 protocols. As confirmed during the initial phase, the proportion of host: bacterial DNA 501 sequenced was improved significantly with CHDD and AS. However, the sequencing yield was suboptimal when CHDD whole genome amplification (WGA) was paired directly with the 502 503 Rapid Barcoding Kit (not systematically tested). The best output was observed when 504 debranched MDA products were barcoded using the Ligation Sequencing Kit, although it requires additional hands-on time and potentially pricier reagents for library preparation. 505 Both versions of the workflows have their own strengths and limitations; for example, the 506 507 rapid workflow requires less hands-on time but may result in relatively low sequencing yield, leading to higher sequencing cost per sample (Fig. 1). In contrast, the high-yield workflow 508 would reduce sequencing cost by providing greater output with only 90 additional minutes 509 for sample processing (Fig. 1). Several studies have already highlighted this difference; [27, 28] 510 511 consequently, users may choose the workflow that best suits their need/budget.

Although there are multiple bioinformatic pipelines available for mNGS-based species 512 identification, only a few have been developed/standardised for diagnosing bloodstream 513 514 infection. The aim of this study was therefore not to benchmark these pipelines; instead, we 515 assessed the utility of one of the well-regarded workflows, CZ ID, in combination with M-15 mNGS. With the 20% (200,000 BPM) abundance cutoff, sequencing accurately identified 3/3 516 517 negative, 28/28 mono-bacterial and 2/4 multi-bacterial species reported in two samples, with 518 >88% DNA classified as the expected species. To determine minimum sequencing yield required to accurately identify bacterial species, we randomly subsampled the reads under 519 520 the established assumption (Fig. 2C) that the proportion of host: bacteria remains consistent 521 throughout a sequencing run [29]. The results demonstrated that the species prediction 522 accuracy with the given cutoff remains nearly identical even with 10 Mbp yield per sample. 523 Therefore, it is not entirely necessary to generate hundreds of Mbp reads/sample to cover 524 \sim 100% of the genome with >20x depth for patient management unless the aim is to utilise 525 this data for hospital outbreak investigation.

With the rapid culture enrichment, only a few species tested reached/crossed $\geq 10^4$ CFU/mL 526 527 threshold under 6 hours, and at least 8 hours of incubation was required to get more comprehensive representation of critically important Gram-positive (n=7) and Gram-negative 528 (n=8) bacterial pathogens. M-15 CHDD and sequencing of a subset of rapid (8-hour) enriched 529 530 samples (5 Gram-positive and 5 Gram-negative) further confirmed our hypothesis: sequence 531 reads from expected bacteria represented >75% of total yield, and similar to BACT/ALERT positive samples, only 10 Mbp reads accurately identified species with the previously assigned 532 abundance threshold. 533

534 Regarding AMR prediction, it is worth highlighting that not all expected molecular 535 mechanisms of antibiotic resistance have been determined [30]. Additionally, a mere 536 presence or absence of genes and/or mutations does not always correlate to phenotypic 537 resistance or susceptibility [30]. Therefore, at present, it is less likely that a sequencing-based 538 approach would match culture-based phenotypic results with 100% accuracy for all the bacterial species commonly identified in BSI. Like species identification, several workflows can 539 predict AMR using mNGS data. The underlying principles, databases and/or accuracy can vary 540 among these workflows for AMR identification [31]. Therefore, it was decided to test 541 542 ResFinder, a well-regarded workflow, with M-15 mNGS, as benchmarking several

workflows/bioinformatic pipelines was not within the scope of this study. M-15 mNGS 543 combined with ResFinder exhibited overall 90.3% accuracy 8.49% major and 15.55% very 544 545 major error with BACT/ALERT positive samples. These proportions closely match with some of 546 the other studies that utilised culture enriched samples for metagenomic sequencing, 547 although very major error rates with M-15 mNGS were found to be marginally lower [20]. 548 With rapid culture-enriched samples, WGS data was used as comparator. Although this is less ideal than comparing with culture-based phenotypic results, we wanted to understand how 549 550 closely mNGS results matched those of reference sequences of bacteria that were used for 551 spiking. With 920 ResFinder AST predictions, mNGS showed 98.7% categorical agreement, and only 1.3% false susceptibility, primarily due to P. aeruginosa, the only species exhibiting 552 553 discordant results. Similar suboptimal results with P. aeruginosa were also observed in the 554 aforementioned study [20]. However, in our case, this likely stemmed from inefficient/uneven 555 DNA amplification due to high GC content of *P. aeruginosa* (66.6%), as we did not observe any 556 lysis/viability issues with culture when CHDD samples were plated on agars (Tab. S2).

557 Considering the overall performance, it seems more work is required in terms of wet/dry lab to make AMR predictions more accurate (e.g., Q30 reads and/or utilizing machine learning 558 models [32]) to be accepted as a replacement of blood culture and phenotypic assays. 559 However, as an addition to existing methods, M-15 mNGS at its current stage still holds 560 561 promise to inform treatment in comparison to empirical antibiotic therapy. For clinical 562 management of BSI or infection in general, the accuracy of empirical treatment can range 563 from 20% to 80% [33-35]. This means that a high proportion of cases receive inappropriate antibiotics until more targeted therapy is administered utilizing the phenotypic AST results 564 565 (conventionally available in 48-72 hours), potentially risking detrimental outcomes for 566 critically ill patients [34]. With the rapid availability of bacterial species and AMR predictions 567 that surpass empiric prescription and therapy, mNGS can significantly refine the choice of 568 antimicrobials, increasing the likelihood of favourable outcomes. That being said, thorough 569 clinical validation would be required for rapid M-15 mNGS to be recommended for clinical 570 implementation.

A possible costly drawback when implementing the rapid enrichment approach was the
necessity to blindly sequence all blood cultures if the culture positive and negative samples
could not be differentiated prior to sequencing. However, when compared to the negative

blood samples, both BACT/ALERT positive and rapid enriched spiked M-15 CHDD blood had 574 152x and 28x higher dsDNA concentration following MDA, meaning any negative samples 575 576 could potentially be filtered out prior to sequencing if their Qubit-measured DNA 577 concentration provides a differentiable signature, as we observed following CHDD and WGA (Tab. S1, S2). However, the exact cutoff must be determined site-wise (different clinical 578 579 settings or in different laboratories) with more negative patient samples before implementation in a clinical setting. It is important to note that this differentiation is only 580 possible with rapid CHDD as direct extraction and amplification would not provide a 581 582 discernible characteristic for negative samples due to the overwhelming abundance of host 583 DNA masking the unique signature from the bacteria (Tab. S2). This approach may incorrectly 584 flag some slow growing and/or bacterial species with high GC% as negative. However, 585 because M-15 mNGS is currently intended to complement existing technologies rather than 586 replacing them, species that might be missed would still be captured with traditional culture-

587 based methods.

It is important to recognise that this study had several limitations. Since we only had access to 588 589 different volumes of surplus EDTA treated blood samples from the suspected BSI cases, stored 590 in a refrigerator for up to five days until reporting was complete, it was decided not to test the 591 rapid enrichment workflow on patient samples. Instead, 15 clinically important bacterial 592 species were chosen for initial validation. This is because the different volume and extended 593 storage of the samples might alter the host/pathogen ratio, affect viability, and/or change the 594 actual growth of the bacteria and therefore might not be an appropriate representative of freshly drawn samples. 595

Also, the rapid and high yield mNGS workflows were benchmarked, and a few batches of
samples were initially processed using R9.4.1 flow cells, before more accurate R10.4.1 kits
became widely available on the market. Therefore, it was decided to continue testing all the
samples with library kits compatible with R9.4.1 flow cells [27]. We believe that the
performance of M-15 CHDD would be further enhanced with the use of newer versions of
kits/flow cells, as a higher proportion of ≥Q20 reads would likely allow mutations associated
with AMR to be more reliably predicted.

604 Conclusions

605	In summary, in this study, we demonstrated that M-15 CHDD paired with a rapid barcoding or
606	ligation sequencing workflow is highly effective at species and AMR gene detection in
607	BACT/ALERT positive and rapid culture enriched samples. This approach can deplete
608	significant amount of host DNA and facilitate rapid bacterial/AMR identification, with a hands-
609	on time of less than 4 (rapid barcoding kit) and 6 hours (ligation sequencing kit), plus time
610	required to generate 10 Mbp (species)/≥50 Mbp (AMR) sequencing yield per sample. The
611	time to achieve this yield can vary depending on the capacity of the flow cells used and/or the
612	number of samples multiplexed in a sequencing run, therefore, it is up to the user to choose
613	the appropriate flow cell and/or number of samples based on their needs. However, we
614	demonstrated that with 8-hour culture enrichment, M-15 mNGS can predict causative
615	bacterial species and accurately detect AMR determinants within 13-15 hours of sample
616	collection, and thus has the potential to improve patient outcomes in BSI.
617	
618	
619	
620	
621	
622	
623	
624	
625	
626	
627	
628	
629	

630 Abbreviations

- 631 AMR: Antimicrobial resistance
- 632 AS: Adaptive sampling
- 633 AST: Antimicrobial susceptibility testing
- 634 ATCC: American Type Culture Collection
- 635 BSI: Bloodstream infection
- 636 BPM: Bases per million
- 637 CFU: Colony-forming units
- 638 CHDD: Chemical host DNA depletion
- 639 dsDNA: Double-stranded DNA
- 640 EUCAST: European Committee on Antimicrobial Susceptibility Testing
- 641 FDA: Food and Drug Administration (USA)
- 642 GC%: Guanine-cytosine content percentage
- 643 mNGS: Metagenomic next-generation sequencing
- 644 Mbp: Megabase pairs
- 645 MDA: Multiple displacement amplification
- 646 NHS: National Health Service (UK)
- 647 ONT: Oxford Nanopore Technologies
- 648 PBS: Phosphate-buffered saline
- 649 qPCR: Quantitative polymerase chain reaction
- 650 RBC: Red blood cells
- 651 WGA: Whole-genome amplification
- 652 WGS: Whole-genome sequencing

653 Funding

- 654 This study was funded by Royal Society Research Grant (RGS\R1\211163) and University of
- 655 Glasgow's Lord Kelvin Adam Smith (LKAS) Ph.D. studentship.

656 Ethical statement

- 657 This study was reviewed and approved by the University of Glasgow College of Medical,
- 658 Veterinary & Life Sciences Ethics Committee (Project No: 200210015) and UK National Health
- 659 Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331). No personal
- 660 information from the patients and healthy volunteers was collected and used in this study.
- 661 Human DNA reads obtained from mNGS were excluded or not utilised for any bioinformatics
- analyses beyond quantifying the number of hosts reads generated.

663 Availability of data and materials

- All the raw sequencing reads (fastq.gz: host excluded) analysed and presented in this study
- are available on European Nucleotide Archive under the study accession "PRJEB80726".

666 Authors' contributions

667 Conceptualisation of this study was carried out by TF and MSIS. Data generation, cleaning,
668 management, formal analysis, and initial draft was written by MSIS. Project investigation,
669 experimental method selection, clinical sample collection, formal review and coordination
670 was done by TF, KB, KO, PE, MEM, CW, MF, and MSIS. TF (RS) and MSIS (LKAS) acquired
671 funding for this project.

672 Acknowledgements

We would like to thank Kareen Macleod for generously providing the reference isolates used
in this study. We also want to express our gratitude to Ryan Carter and Ângelo Mendes for
their help and input on this project.

676

677


References 679

680 1. Ikuta KS, Lucien R. Swetschinski, Gisela R. Aguilar, Fablina Sharara, Tomislav Mestrovic, 681 Authia P. Gray, Nicole D. Weaver: Global mortality associated with 33 bacterial 682 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 683 **2019.** Lancet 2022, **400:**2221-2248. 2. 684 Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-685 Loeches I, Leone M, Lupu MN, Vincent JL, Investigators I: Sepsis in Intensive Care Unit 686 Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum 687 Infect Dis 2018, 5:ofy313. Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR: Blood Culture 688 3. 689 Turnaround Time in U.S. Acute Care Hospitals and Implications for Laboratory 690 Process Optimization. J Clin Microbiol 2018, 56:10-1128. 691 4. Paharik AE, Schreiber HLt, Spaulding CN, Dodson KW, Hultgren SJ: Narrowing the 692 spectrum: the new frontier of precision antimicrobials. Genome Med 2017, 9:110. 693 Chiu CY, Miller SA: Clinical metagenomics. Nature Reviews Genetics 2019, 20:341-5. 694 355. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, 695 6. 696 Turner DJ, Wain J, et al: Nanopore metagenomics enables rapid clinical diagnosis of 697 bacterial lower respiratory infection. Nat Biotechnol 2019, 37:783-792. 698 7. Trung NT, Hien TT, Huyen TT, Quyen DT, Van Son T, Hoan PQ, Phuong NT, Lien TT, Binh MT, 699 Van Tong H, et al: Enrichment of bacterial DNA for the diagnosis of blood stream 700 infections. BMC Infect Dis 2016, 16:235. 701 8. Marotz CA, Sanders JG, Zuniga C, Zaramela LS, Knight R, Zengler K: Improving saliva 702 shotgun metagenomics by chemical host DNA depletion. Microbiome 2018, 6:1-9. 703 9. Heravi FS, Zakrzewski M, Vickery K, Hu H: Host DNA depletion efficiency of 704 microbiome DNA enrichment methods in infected tissue samples. J Microbiol 705 Methods 2020, 170:105856. 706 10. McQuillan JS, Wilson MW: 'Ready Mixed', improved nucleic acid amplification assays 707 for the detection of Escherichia coli DNA and RNA. J Microbiol Methods 2019, 708 **165:**105721. 709 11. Lee CS, Wetzel K, Buckley T, Wozniak D, Lee J: Rapid and sensitive detection of 710 Pseudomonas aeruginosa in chlorinated water and aerosols targeting gyrB gene 711 using real-time PCR. J Appl Microbiol 2011, 111:893-903. 712 12. Wood C, Sahl J, Maltinsky S, Coyne B, Russakoff B, Yague DP, Bowers J, Pearson T: 713 SaQuant: a real-time PCR assay for quantitative assessment of Staphylococcus 714 aureus. BMC Microbiol 2021, 21:174. 715 13. Bohl JA, Lay S, Chea S, Ahyong V, Parker DM, Gallagher S, Fintzi J, Man S, Ponce A, Sreng 716 S, et al: Discovering disease-causing pathogens in resource-scarce Southeast Asia 717 using a global metagenomic pathogen monitoring system. Proc Natl Acad Sci USA 718 2022, **119:**e2115285119. 719 14. Miles AA, Misra SS, Irwin JO: The estimation of the bactericidal power of the blood. J 720 Hyg (Lond) 1938, **38:**732-749. 721 15. Nurk S, Koren S, Rhie A, Rautiainen M, Bzikadze AV, Mikheenko A, Vollger MR, Altemose 722 N, Uralsky L, Gershman A, et al: The complete sequence of a human genome. Science 723 2022, 376:44-53. 724 16. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe 725 RL, Rebelo AR, Florensa AF, et al: ResFinder 4.0 for predictions of phenotypes from 726 genotypes. J Antimicrob Chemother 2020, 75:3491-3500. 727 17. Li H: Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 2018, 728 **34:**3094-3100.

729	18.	Hall M: Rasusa: Randomly subsample sequencing reads to a specified coverage.
730		Journal of Open Source Software 2022, 7: 3941.
731	19.	Giske CG, Turnidge J, Canton R, Kahlmeter G, Committee ES: Update from the
732		European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin
733		Microbiol 2022, 60: e0027621.
734	20.	Harris PNA, Bauer MJ, Lueftinger L, Beisken S, Forde BM, Balch R, Cotta MO,
735		Schlapbach L, Raman S, Shekar K: Rapid nanopore sequencing and predictive
736		susceptibility testing of positive blood cultures from intensive care patients with
737		sepsis. Microbiology spectrum 2024, 12: e03065-03023.
738	21.	Huang TH, Tzeng YL, Dickson RM: FAST: Rapid determinations of antibiotic
739		susceptibility phenotypes using label-free cytometry. Cytometry A 2018, 93:639-648.
740	22.	Ospino MC, Engel K, Ruiz-Navas S, Binns WJ, Doxey AC, Neufeld JD: Evaluation of
741		multiple displacement amplification for metagenomic analysis of low biomass
742		samples. ISME Commun 2024, 4: ycae024.
743	23.	Sobol MS, Kaster AK: Back to Basics: A Simplified Improvement to Multiple
744		Displacement Amplification for Microbial Single-Cell Genomics. Int J Mol Sci 2023,
745		24: 4270.
746	24.	Wang MC, Lin WH, Yan JJ, Fang HY, Kuo TH, Tseng CC, Wu JJ: Early identification of
747		microorganisms in blood culture prior to the detection of a positive signal in the
748		BACTEC FX system using matrix-assisted laser desorption/ionization-time of flight
749		mass spectrometry. J Microbiol Immunol Infect 2015, 48:419-424.
750	25.	Neyestani Z, Khademi F, Teimourpour R, Amani M, Arzanlou M: Prevalence and
751		mechanisms of ciprofloxacin resistance in Escherichia coli isolated from
752		hospitalized patients, healthy carriers, and wastewaters in Iran. BMC Microbiol
753		2023, 23: 191.
754	26.	Valdes AM, Walter J, Segal E, Spector TD: Role of the gut microbiota in nutrition and
755		health. BMJ 2018, 361:k2179.
756	27.	Ni Y, Liu X, Simeneh ZM, Yang M, Li R: Benchmarking of Nanopore R10.4 and R9.4.1
757		flow cells in single-cell whole-genome amplification and whole-genome shotgun
758		sequencing. Comput Struct Biotechnol J 2023, 21:2352-2364.
759	28.	ONT: Premium whole genome amplification-Oxford Nanopore Technologies.
760		Ligation sequencing gDNA. SQK-LSK109. 2022.
761	29.	Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R: Rapid identification of pathogens,
762		antibiotic resistance genes and plasmids in blood cultures by nanopore
763		sequencing. Sci Rep 2020, 10: 7622.
764	30.	Su M, Satola SW, Read TD: Genome-Based Prediction of Bacterial Antibiotic
765		Resistance. J Clin Microbiol 2019, 57:10.1128/jcm. 01405-01418.
766	31.	Doyle RM, O'Sullivan DM, Aller SD, Bruchmann S, Clark T, Coello Pelegrin A, Cormican
767		M, Diez Benavente E, Ellington MJ, McGrath E, et al: Discordant bioinformatic
768		predictions of antimicrobial resistance from whole-genome sequencing data of
769		bacterial isolates: an inter-laboratory study. <i>Microb Genom</i> 2020, 6:e000335.
770	32.	Ali T, Ahmed S, Aslam M: Artificial Intelligence for Antimicrobial Resistance
771		Prediction: Challenges and Opportunities towards Practical Implementation.
772		Antibiotics (Basel) 2023, 12: 523.
773	33.	Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N: Incidence and outcome of
774		inappropriate in-hospital empiric antibiotics for severe infection: a systematic
775		review and meta-analysis. Crit Care 2015, 19: 1-12.
776	34.	Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP,
777		Palmore TN, Rhee C, et al: Inappropriate empirical antibiotic therapy for
778		bloodstream infections based on discordant in-vitro susceptibilities: a

779 780 781 782 783 784	35.	retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2021, 21:241-251. Luo Y, Guo Z, Li Y, Ouyang H, Huang S, Chen Y, Li K, Ji Y, Zhu H, Luo W, et al: Appropriateness of Empirical Antibiotic Therapy in Hospitalized Patients with Bacterial Infection: A Retrospective Cohort Study. Infect Drug Resist 2023, 16:4555- 4568.
785		
786		
787		
788		
789		
790		
791		
792		
793		
794		
795		
796		
797		
798		
799		
800		

Supplementary Figures, tables and protocols 801



802 803

Fig. S1: Accuracy of species prediction with varying sequencing yield (100 Mbp to 10 Mbp),

identified by subsampling the (A) reads from 17 bacterial species from the 30 BACT/ALERT positive 804 805 blood culture samples and (B) 10 rapid (8-hours) culture enriched spiked blood samples. Analysis was

- performed similarly using CZ ID with the same abundance threshold for all the species tested. Colored 806
- 807 gradient highlights the species that passed the initial threshold filter and their abundance (base per
- million) in the CHDD samples that were sequenced. 808




Fig. S2: Antibiotic susceptibility profiles predicted with varying sequencing yield (>100 Mbp to 10

Mbp/sample) using subsampled reads from the 30 BACT/ALERT positive blood culture samples. (A) The heatmap is showing antimicrobial resistance profiles and (B) the barplot highlights the number of

- antimicrobials from different antibiotic classes identified with different sequencing yield for
- BACT/ALERT positive samples.




Fig. S3: Antibiotic susceptibility profiles predicted with varying sequencing yield (>50 Mbp to 10

Mbp/sample) using the subsampled reads from 10 rapid culture enriched (8-hours) spiked blood samples. (A) The heatmap shows antimicrobial resistance profiles and (B) the barplot highlights the

number of antimicrobials from different antibiotic classes identified with different sequencing yield for

- rapid culture enriched spiked blood samples.

833 Tab. S1: Double stranded DNA concentration of three BACT/ALERT negative (BCN01 to BCN03) and 30

BACT/ALERT positive blood culture (BCP) samples guntified by Qubit following M-15 CHDD and 60 834

minutes of multiple displacement amplification with REPLI-g kit. As controls, six samples (BCN01 to 835

836 BCN03 and BCP01 to BCP03) were also extracted directly and amplified similarly for 60 minutes

837 without CHDD. Viability of bacterial following M-15 CHDD was confirmed by plating the supernatant

838 on nutrient and blood agar media.

Sample	Accession	Organism	Culture	GC content (%)	Viability after M-15 CHDD	CHDD samples DNA (ng/µL)	No-CHDD samples DNA (ng/μL)
BCN01	ERR13759391	Not detected	Negative	N/A	N/A	1.6	733
BCN02	ERR13759392	Not detected	Negative	N/A	N/A	2.8	767
BCN03	ERR13759393	Not detected	Negative	N/A	N/A	5.5	760
BCP01	ERR13759394	S. pyogenes	Positive	38.5	Viable	209	490
BCP02	ERR13759395	S. aureus	Positive	32.8	Viable	201	920
BCP03	ERR13759396	E. coli	Positive	50.8	Viable	350	940
BCP04	ERR13759397	S. pyogenes	Positive	38.5	Viable	291	Not tested
BCP05	ERR13759398	S. epidermidis	Positive	33.0	Viable	950	Not tested
BCP06	ERR13759399	S. epidermidis	Positive	33.0	Viable	620	Not tested
BCP07	ERR13759400	B. luteolum	Positive	67.8	Viable	17.4	Not tested
BCP08	ERR13759401	M. luteus	Positive	74.0	Not viable	9.44	Not tested
BCP09	ERR13759402	P. mirabilis	Positive	38.8	Viable	235	Not tested
BCP10	ERR13759403	S. agalactiae	Positive	35.5	Viable	77.8	Not tested
BCP11	ERR13759404	E. coli	Positive	50.8	Viable	1480	Not tested
BCP12	ERR13759405	E. coli	Positive	50.8	Viable	342	Not tested
BCP13	ERR13759406	K. michiganensis	Positive	55.5	Viable	1390	Not tested
BCP14	ERR13759407	E. coli	Positive	50.8	Viable	843	Not tested
BCP15	ERR13759408	K. variicola	Positive	57.3	Viable	1340	Not tested
BCP16	ERR13759409	S. agalactiae	Positive	35.5	Viable	325	Not tested
BCP17	ERR13759410	L. adecarboxylata	Positive	52.55	Viable	111	Not tested
BCP18	ERR13759411	E. coli	Positive	50.8	Viable	1170	Not tested
BCP19	ERR13759412	S. aureus	Positive	32.8	Viable	326	Not tested
BCP20	ERR13759413	S. maltophilia	Positive	66.7	Viable	18.1	Not tested
BCP21	ERR13759414	S. epidermidis	Positive	33.0	Viable	440	Not tested
BCP22	ERR13759415	E. faecalis	Positive	37.5	Viable	432	Not tested
BCP23	ERR13759416	K. pneumoniae	Positive	57.3	Viable	680	Not tested
BCP24	ERR13759417	P. mirabilis	Positive	38.7	Viable	860	Not tested
BCP25	ERR13759418	E. coli	Positive	50.8	Viable	1033	Not tested
BCP26	ERR13759419	S. gallolyticus	Positive	37.69	Viable	297	Not tested
BCP27	ERR13759420	S. aureus	Positive	32.8	Viable	228	Not tested
BCP28	ERR13759421	A. xylosoxidans	Positive	64.0	Viable	84	Not tested
BCP29	ERR13759422	S. epidermidis	Positive	33.0	Viable	406	Not tested
BCP30	ERR13759423	C. jejuni	Positive	30.3	Viable	348	Not tested

Tab. S2: Double stranded DNA concentration of three 8-hour culture enriched sterile blood (HB1 to

HB3) versus ten spiked blood (1-10 CFU) samples following 60 minutes of multiple displacement

amplification with REPLI-g kit with and without M-15 chemical host DNA depletion (CHDD) measured

by Qubit. Viability of bacteria following M-15 CHDD was confirmed by plating the supernatant on

nutrient and blood agars.

Sample	Organism	Culture	GC content (%)	Viability after M- 15 CHDD	CHDD samples DNA (ng/µL)	No-CHDD samples DNA (ng/μL)
HB1	Not detected	Negative	NA	N/A	4.2	652
HB2	Not detected	Negative	NA	N/A	8.1	487
HB3	Not detected	Negative	NA	N/A	4.18	513
RESB1	S. aureus	Positive	32.8	Viable	131	510
RESB2	E. faecium	Positive	37.8	Viable	122	611
RESB3	S. pyogenes	Positive	38.5	Viable	140	377
RESB4	S. agalactiae	Positive	35.6	Viable	177	647
RESB5	S. pneumoniae	Positive	39.7	Not viable	83	550
RESB6	P. aeruginosa	Positive	66.6	Viable	43	449
RESB7	K. quasipneumoniae	Positive	57.2	Viable	213	714
RESB8	A. baumannii	Positive	39	Viable	156	699
RESB9	E. coli	Positive	50.8	Viable	248	892
RESB10	P. mirabilis	Positive	38.88	Viable	233	621

Tab. S3: AMR gene profile (genes expected based on whole genome sequencing data) of the 8-hour

culture-enriched blood samples chosen for sequencing (n=10). Following M-15 mNGS, sequencing

reads were analysed with ResFinder to match and confirm the presence/absence of the same AMR

determinants expected from the species initially utilised for spiking. Prediction accuracy of AMR

(Match%) was determined comparing the ResFinder predicted phenotypic AST results of M-15 mNGS versus previously sequenced clinical/ATCC strains.

Sampl e	Accession	Organism	Source	Genes expected	Genes found (M- 15)	Gene Match	Phenotyp e Match (%)
RESBO 1	ERR13759428	S. aureus	NCTC 12493	mecA, ant(9)-Ia, erm(A), tet(K)	mecA, ant(9)-Ia, erm(A), tet(K)	4/4	100
RESBO 2	ERR13759429	E. faecium	Clinical isolate	aac(6')-II, ant(6)-Ia, aph(3')-III, aph(2'')-Id, erm(B), msr(C), Isa(E), tet(M)	aac(6')-II, ant(6)-Ia, aph(3')-III, aph(2'')- Id, erm(B), msr(C), Isa(E), tet(M)	8/8	100
RESBO 3	ERR13759430	S. pyogenes	Clinical isolate	-	-	0/0	100
RESBO 4	ERR13759431	S. agalactiae	Clinical isolate	mre(A)	mre(A)	1/1	100
RESBO 5	ERR13759432	S. pneumoniae	ATCC 6303	-	-	0/0	100
RESBO 6	ERR13759433	P. aeruginosa	ATCC 27853	aph(3')-IIb, blaPAO, blaOXA-396, fosA, catB7, crpP	catB7, crpP	6/2	86.9
RESBO 7	ERR13759434	K. quasipneum oniae	ATCC 700603	ant(2'')-la, blaOKP-B, blaSHV-18, blaOXA-2, fosA, OqxA, OqxB, sul1	ant(2'')-Ia, blaOKP- B, blaSHV-18, blaOXA-2, fosA, OqxA, OqxB, sul1	8/8	100
RESBO 8	ERR13759435	A. baumannii	Clinical isolate	blaOXA-343, blaADC-25	blaOXA-343, blaADC-25	2/2	100
RESBO 9	ERR13759436	E. coli	Clinical isolate	aph(3'')-Ib, aph(6)-Id, blaTEM-1C, sul2	aph(3'')-Ib, aph(6)- Id, blaTEM-1C, sul2	4/4	100
RESB1 O	ERR13759437	P. mirabilis	Clinical isolate	tet(J)	tet(J)	1/1	100

- Tab. S4: Primer, probe sequences and their reaction concentrations used in this study for detecting
- universal 16S (bacteria) and 18S Ribosomal ribonucleic acid-rRNA (host) genes and species-specific
- genes to identify three bacterial species, (Escherichia coli (EC), Pseudomonas aeruginosa (PA), and
- Staphylococcus aureus (SA)) used for initial spiking and benchmarking experiments.

Genes	Primer/Probe name	Primer/Probe Conc (nM)	Sequence (5'-3')	Reference
	16S rRNA_341_F	100	CCTACGGGAGGCAGCAG	
16S rRNA	16S rRNA_534_R	400 -	ATTACCGCGGCTGCTGG	 Heravi et al [9].
	16S rRNA_P	100	FAM-CCGCGTGWRTGAWGAAGGYCTTCG-BHQ1	This study
	18S rRNA_756_F	400	GGTGGTGCCCTTCCGTCA	
18S rRNA	18S rRNA_877_R	400 -	CGATGCGGCGGCGTTATT	 Heravi et al [9].
	18S rRNA_P	100	Hex- ACCCAAAGACTTTGGTTTCCCGGA- BHQ1	This study
	EC_ybbW_F	00	TGATTGGCAAAATCTGGCCG	
EC_ybbW	EC_ybbW_R	- 80 -	GAAATCGCCCAAATCGCCAT	McQuillan et al [10].
	EC_ybbW_P	40	FAM-CCGCCGAAAACGATATAGATGCACGG- BHQ1	[10].
	PA_GB722_F	- 500 -	GGCGTGGGTGTGGAAGTC	
PA_GB722	PA_GB722_R	- 500 -	TGGTGAAGCAGAGCAGGTTCT	Lee et al [11].
	PA_GB722_P	250	FAM-TGCAGTGGAACGACA- BHQ1	_
	SA_SaQuant_F	- 1000 -	AACTACTAGGGGAGCCTAATRAT	_
SA_SaQuant	SA_SaQuant_R	1000 -	GGTACTAACCAAATCAGGTCATAA	Wood et al [12].
	SA_SaQuant_P 200		FAM-TGGCTGAGATGAAYTGTTCAGACCC- BHQ1	_

900 Supplement Protocol: M-15 mNGS

901 Consumables

Name	Concentration/units	Commercial source	Comments
Saponin	Final concentration 2.25%	Tokyo chemical industry, Cat: S0019	To make a 4.5% or 2.25% w/v solution, dissolve 4.5/2.25 grams of Saponin into 50 ml sterile nuclease free H ₂ O. Mix thoroughly until dissolved. Adjust the volume to 100ml. Sterilize using 0.2 μm filter, and store at 4 °C for up to 3 weeks
NaCl	5M	Promega, Cat: V4221	NA
DNase I	300 units/μL	Invitrogen, Cat: 18047019	NA
DNase I buffer	10x solution	NEB, Cat: B0303SVIAL	10x buffer = 10 mM Tris HCl, 2.5 mM MgCl2, 0.5 mM CaCl2
Trypsin-EDTA	0.05%, phenol red	ThermoFisher Cat: 25300054	NA
Molecular grade H20	NA	Qiagen, Cat: 129114	NA
DPBS	1x solution	ThermoFisher Cat: 14190144	Without calcium, magnesium, or phenol
T7 Endonuclease I	NA	NEB, Cat: M0302S or M0302L	NA
DNA binding beads	NA	Aline biosciences, Cat: C-1003-50	NA
Molecular grade ethanol	NA	Sigmaaldrich, Cat: 51976-500ML-F	NA

Name	Concentration/units	Commercial source	Comments
REPLI-g Single Cell Kit	NA	Qiagen, Cat: 150343 or 150345	NA
Qubit dsDNA Be assay Kit	NA	ThermoFisher, Cat: Q32853	NA
Qubit assay tubes	NA	ThermoFisher, Cat: Q32856	NA
Rapid Barcoding Kit	NA	ONT, Cat: SQK- RBK004	Required for the rapid sequencing protocol
Long Fragment Buffer Expansion	NA	ONT, Cat: EXP- LFB001	Required for the rapid sequencing protocol
Ligation Sequencing Kit	NA	ONT, Cat: SQK- LSK109	Required for the high yield protocol
Native Barcoding Expansion Kit	NA	ONT, Cat: EXP- NBD196	Required for the high yield protocol
NEBNext Ultra II End Repair/dA- Tailing Module	NA	NEB, Cat: E7546L	Required for the high yield protocol
Blunt/TA Ligase Master Mix	NA	NEB, Cat: M0367L	Required for the high yield protocol
NEBNext Quick Ligation Module	NA	NEB, Cat: E6056L	Required for the high yield protocol
Flow Cell Priming Kit	NA	ONT, Cat: EXP- FLP002	Required for both protocols
Flow Cell Wash Kit	NA	ONT, Cat: EXP- WSH004	Required for both protocols
ONT Flow Cell R9.4.1	NA	ONT, Cat: FLO- MIN106 or FLO- FLG001	Required for both protocols
Magnetic rack/plate holder	NA	ThermoFisher, Cat: 12331D and 12321D	NA

Name	Concentration/units	Commercial source	Comments
PCR Tube Strip with Attached Flat Caps	NA	ThermoFisher, Cat: AB2000	NA
1.5 ml DNA LoBind tubes	NA	Eppendorf, Cat: 0030108051-250EA	Use LoBind tubes
2 ml round bottom tubes	NA	Starlab, Cat: S1620- 2700-C or Eppendorf, Cat: 0030120094	Avoid using LoBind tubes
Pipettes and pipette tips P2, P10, P20, P100, P200, P1000, Multichannel	NA	Any	NA
Centrifuge /Microplate centrifuge	NA	Any	NA
Vortex mixer	NA	Any	NA
Thermal cycler	NA	Any	NA
Heating block for 1.5/2 mL tubes	NA	Any	NA
Sequencing device	NA	Flongle, MinION Mk1B, GridION	NA
Device for live basecalling	NA	GridION or A powerful laptop	A laptop with minimum 8 Gb GPU (RTX 3060 or higher), 16 GB Ram, 1 Tb M.2 NVMe SSD

Disclaimer: Some parts of the following protocol has been copied directly from the 902

manufacturer's official website or from the kit manual. Therefore, all the proprietary 903

information mentioned below remains the sole property of the kits manufacturer. 904

906 Before sample preparation

- 907 It is important to divide all reagents into smaller aliquots to avoid multiple freeze-thaw cycles908 and reduce the likelihood of cross-contamination.
- 909 Warm up 0.05% trypsin EDTA at 37°C. Prepare 1x DNase I buffer and store in the fridge
- 910 before use. Make a fresh batch of REPLI-g Master Mix following manufacturer's instructions.
- 911 Take out aliquots of Buffer D2, Stop Solution, and any other reagents from the freezer, and
- store in the refrigerator or on ice until needed. Thaw all the reagents at room temperature or
- 913 on ice as per manufacturers recommendation.
- 914 This protocol can be used on BD BACTEC (Becton, Dickinson and Company, NJ, USA) or any
- 915 blood culture (FPBC) samples flagged positive with an automated culture system. Protocol M-
- 916 15 mNGS can also be applied to rapid culture enriched blood samples (REBC; for example, 1-
- 917 10 mL patient blood samples incubated for 8 hours in BD BACTEC media bottles), once the
- 918 enriched sampled have at least 10³ CFU/mL bacterial concentration. FPBC samples can be
- 919 used directly for CHDD; however, REBC samples need to be pre-processed to concentrate the
- sample before continuing with this protocol. It is crucial to use fresh samples for CHDD, as
- 921 frozen or improperly stored samples can lead to the lysis of bacterial cells. This may lead to a922 considerable loss of bacterial DNA during CHDD.

923 Pre-processing REBC samples

- 924 Transfer 1.5 mL REBC samples aseptically to a 2 mL round bottom microcentrifuge tube and
- 925 spin at 8,000xg for 5 minutes. Slowly aspirate the supernatant without disturbing the pellet
- and gently resuspend the pellet in 800 μL 2.25% saponin. Proceed to the step 2 of CHDD
- 927 protocol below.
- 928 Note* It is important to use round/wide bottom 2 mL microcentrifuge tubes to minimize bacterial cell loss while929 aspirating the supernatant during the initial washing steps.
- 930

931

933 Host depletion

- 934 1. Add 400 μL FPBC sample to 400 μL 4.5% saponin (final saponin concentration will be 2.25%
 935 after mixing) in a 2 mL wide bottom sterile microcentrifuge tube and gently pipette mix for at
 936 least 4 to 5 times.
- 937 $\,$ 2. Add 1 μL DNase I (300 units/ μL) to the REBC/FPBC sample, pulse vortex at low speed for 5 $\,$
- seconds and incubate the sample at 25°C in a heating block for 10 minutes at 800 rpm.
- 939 Note* Adding DNase I decreases the viscosity of the sample by degrading a substantial amount of DNA
- 940 (desirably from the host) after selective host cell lysis. The DNA released from the host cells can be extremely
- 941 sticky, and often adhere to pipette tips or microfuge tubes. As a result, there's a risk of losing desired/targeted
- bacterial cells because they might adhere to the sticky host DNA and get affixed to the pipette tips and/or
- 943 microcentrifuge tube.
- 944 3. Perform a quick spin and add 800 μL molecular grade water to the sample. Pipette mix 4 to
 945 5 times and incubate for 1 minute at room temperature.
- **946** 4. Add 44 μL 5 M molecular grade NaCl (final concentration is 137 mM; same as PBS) to the
- sample, invert the tubes 3 to 4 times to mix and centrifuge at 10,000x g for 5 minutes.
- 948 5. Carefully remove the supernatant without touching or disturbing the pellet and resuspend
- 949 in 1 mL molecular grade 1x Dulbecco's Phosphate Buffered Saline (DPBS, Without calcium,
- 950 magnesium, or phenol).
- 951 6. Centrifuge the sample at 10,000x g for 3 minutes and carefully remove the supernatant952 without touching or disturbing the pellet.
- 953 7. Resuspend the pellet in 398 μL 1x DNase I buffer, add 2 μL DNase I (300 units/μL) to the
- sample and incubate at 37°C with shaking at 800 RPM for 15 minutes.
- 8. Following incubation, add 1 mL 0.05% trypsin EDTA directly to the sample, pipette mix at
- 956 least 8 to 10 times and incubate at room temperature for 1 minute.
- 957 Note* Some bacterial cells may form aggregates in the sample, so adding 0.05% trypsin EDTA can separate the
- 958 cells and ensure an even distribution for subsequent procedures. The trypsinisation step does not affect
- bacterial viability and/or cell wall integrity.
- 960 9. Repeat step 6 and resuspend the pellet in 1 mL 1x DPBS.

- 961 Note* This is the end of host depletion with M-15. After this, 4 μL of host depleted bacterial cell material in
- 962 DPBS from step 9 can be used directly for alkaline lysis and whole genome amplification (WGA; protocol 1) using
- 963 the REPLI-g Single Cell Kit.

964 DNA extraction and Whole Genome Amplification

965 10. Prepare sufficient Buffer D2 in a PCR tube for the total number of 12 reactions.

Reagent	Volume (µL)
DTT, 1M	3
Buffer DLB	33
Total	36

966 Note* Buffer D2 should not be stored longer than 2 months at-20 °C.

967 11. Place 4 μL cell material into a PCR tube containing 3 μL buffer D2. Mix by flicking the tube

- and centrifuge briefly.
- 969 12. Incubate at 65°C for 10 min with heated lid on and then add 3 μL Stop Solution. Mix by

970 flicking the tube and centrifuge briefly. Prepare a master mix according to the instruction

971 below.

Reagent	Volume (µL)
REPLI-g sc Reaction Buffer	14
REPLI-g sc DNA Polymerase	1
Total	15

- 972 Note* Avoid using H₂O for preparing the master mix.
- 973 13. For each reaction, add 5 μL DNA from step 12 and incubate at 30°C for 1 hour with974 heated lid off.
- 975 14. Inactivate REPLI-g sc DNA Polymerase by heating the sample for 3 min at 65°C with
- 976 heated lid on.
- 977 Note* After this step amplified host depleted DNA can be diluted 5-fold in molecular grade H₂O, measured with
- 978 Qubit Br assay and used directly for debranching and subsequently sequencing library preparation.

979 Debranching and bead cleanup

980 15. In a clean 0.2 mL PCR tube, mix the reagents for debranching in the following order.

Reagent	Volume (µL)
600 ng of amplified DNA	To make 30 μL
NEBuffer 2	3
T7 Endonuclease I	1.5
Nuclease free H_2O	25.5- To make 30 μL
Total	30

982 16. Mix the reagents by flicking the tube and centrifuge briefly. Incubate the reaction for 10983 minutes at 37°C.

984 17. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.

985 18. Add 15 μL of the bead suspension (0.5x) to the DNA sample and mix by pipetting.

- 986 19. Incubate for 5 minutes at room temperature.
- 987 20. Spin down and pellet the sample on a magnetic rack/plate until supernatant is clear and988 colourless. Keep the tube on the magnet, and pipette off the supernatant.
- 989 21. Keeping the tube on the magnet, wash the beads with 200 μ L of freshly prepared 70%
- ethanol without touching/disturbing the pellet. Remove the ethanol carefully using apipette and discard.
- **992** 22. Repeat the previous ethanol washing step.
- 993 23. Spin down and put the tube back on the magnetic rack/plate. Pipette off any residual
- ethanol. Open the lid and allow the tubes to dry for ~30 seconds, but do not dry thepellet to the point of cracking.
- 996 24. Remove the tube from the magnetic rack/plate and resuspend the pellet in 15 μL997 nuclease-free water. Incubate for 2 min at room temperature.
- 998 25. Pellet the beads on a magnet until the eluate is clear and colourless.
- 999 26. Remove and retain 12 μ L of eluate into a clean 0.2 mL PCR tube.
- 1000 Note* This is the end of debranching and DNA cleanup. After this step, cleaned and debranched DNA products
- 1001 can be used for library preparation with Rapid Barcoding (rapid but low yield) or Ligation sequencing kit (highest1002 yield).

1004 Rapid barcoding (low-medium yield protocol)

1005 Barcoding

1006 1. Combine the following components per PCR tube:

Reagent	Volume (µL)
Debranched, cleaned	7.5
DNA (400 ng)	7.5
Fragmentation Mix	2.5
(RB01-12)	2.5
Total	10

- 1008 2. Mix the reagents by flicking the tube and spin briefly.
- 1009 3. Incubate the samples at 30°C in a thermal cycler for 1 minute and 80°C for 1 minutes with1010 heated lid off.
- 1011 4. Spin and pool all the rapid barcoded DNA in 1.5 mL Eppendorf DNA LoBind tube to make
 1012 1,200 ng in a volume of 50 μL. Example, for 6 samples, take 200 ng (200 x 6 = 1,200 ng)
 1013 DNA per sample.
- 1014 5. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.
- 1015 6. Add 25 μL (0.5x) of resuspended beads to the sample and mix by flicking the tube multiple1016 times.
- **1017** 7. Incubate the tube for 5 minutes at room temperature.
- **1018** 8. Spin down the sample and pellet on a magnetic rack/plate until the supernatant is clear
- and colourless. Keep the tube on the magnet, and carefully pipette off the supernatant.
- 9. Wash the beads with 250 μl long Fragment Buffer (LFB) without touching/disturbing the
 pellet. Remove LFB carefully using a pipette and discard.
- 1022 Note* Flick the beads to resuspend, spin and put back on magnet and remove supernatant using a pipette. Long
 1023 Fragment Buffer Expansion (EXP-LFB001) can be purchased separately from ONT.
- 1024 10. Repeat the previous LFB washing step.

- 1025 11. Spin down and place the tube back on the magnet. Pipette off any residual supernatant.
- 1026 Allow to dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1027 12. Remove the tube from the magnetic rack/plate and resuspend the pellet in 22 µL Elution
- **1028** Buffer (EB). Spin down briefly and incubate for 2 minutes at room temperature.
- 1029 13. Pellet the beads on a magnetic rack/plate until the eluate is clear and colourless, for at1030 least 1 minute.
- 1031 14. Remove and retain 20 μL of eluate containing the DNA library into a clean 1.5 mL
 1032 Eppendorf DNA LoBind tube.
- 1033 Rapid adapter ligation and loading
- 1034 15. Quantify 1 μL rapid barcoded and cleaned DNA using a Qubit fluorometer.
- 1035 16. Add 1 μL rapid adaptor (RAP) to 10 μL of barcoded DNA in EB in a PCR tube, flick multiple
- 1036 times to mix, spin briefly and incubate for 10 minutes at 20°C with the heated lid off.
- 1037 17. Load 100 ng (51.36 fmol; considering 3kb product size) of final prepared library onto a1038 flow cell following manufacturers recommendation.
- 1039
- 1040
- 1041
- 1042
- 1043
- 1044
- 1045
- 1046
- 1047
- 1040
- 1048
- 1049

Ligation sequencing (high yield protocol) 1050

1051 End prep

1052 1. Combine the following components per PCR tube:

Reagent	Volume (µL)
Ultra II End-prep reaction buffer	0.875
Ultra II End-prep enzyme mix	0.75
Debranched, cleaned DNA	12
Total	13.625

1053

- 1054 2. Mix gently by flicking the tube, and spin down.
- 1055 3. Using a thermal cycler, incubate at 20°C for 5 minutes with heated lid off.
- 1056 4. Incubate at 65°C for 5 minutes with heated lid on.

1057 Native barcode ligation and cleanup

1058 5. Combine the following components per PCR tube:

Reagent	Volume (µL)
Native Barcode	1.25
Blunt/TA Ligase Master Mix	6
End prepped DNA	6
Total	13.25

- 6. Mix gently by flicking the tube, and spin down. 1060
- 1061 7. Incubate the reaction for 10 minutes at 20°C with heated lid off.
- 1062 8. Resuspend the AMPure XP beads by vortexing.
- 1063 9. Add 13.25 μL of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1064 10. Incubate for 5 minutes at room temperature.
- 1065 11. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the 1066 tube on the magnet, and pipette off the supernatant.
- 1067 12. Keep the tube on the magnet and wash the beads with 200 μ L of freshly prepared 70% ethanol
- 1068 without disturbing the pellet. Remove the ethanol using a pipette and discard.

- 1069 13. Repeat the previous step.
- 1070 14. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
- 1071 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1072 15. Remove the tube from the magnetic plate and resuspend pellet in 15 μ L nuclease-free water.
- 1073 Incubate for 2 min at room temperature.
- 1074 16. Pellet the beads on a magnet until the eluate is clear and colourless.
- 17. Remove and retain 12 μ L of eluate into a clean PCR tube. 1075
- 1076 Measure DNA concentration with Qubit and pool all the barcoded DNA in 1.5 mL Eppendorf DNA
- 1077 LoBind tube to make 350 ng in a volume of 30 µL H2O. Example, for 6 samples, take 58.33 ng (58.33 x 1078 6 = 350 ng) DNA per sample.

Adapter ligation and cleanup and loading 1079

1080 18. Combine the following components:

Reagent	Volume (µL)
Pooled barcoded DNA (350 ng)	30
Adapter Mix II (AMII)	5
Ligation Buffer (LNB)	10
Quick T4 DNA Ligase	5
Total	50

- 1082 19. Ensure the components are thoroughly mixed by pipetting, and spin down.
- 1083 20. Incubate the reaction for 15 minutes at 20°C.
- 1084 21. Resuspend the AMPure XP beads by vortexing.
- 1085 22. Add 25 μ L (0.5x) of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1086 23. Incubate for 5 minutes at room temperature.
- 24. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the 1087 1088 tube on the magnet, and pipette off the supernatant.
- 1089 25. Wash the beads by adding 250 μ l long Fragment Buffer (LFB).
- 1090 Note* Do not flick the beads to resuspend. Just gently wash and remove the supernatant using a
- 1091 pipette and discard.
- 1092 26. Repeat the previous step.
- 1093 27. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
- 1094 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1095 28. Remove the tube from the magnetic rack and resuspend the pellet in 17 µL Elution Buffer (EB).
- 1096 Spin down and incubate for 2 minutes at room temperature.

- 1097 29. Pellet the beads on a magnet until the eluate is clear and colourless, for at least 1 minute.
- 1098 30. Remove and retain 15 μL of eluate containing the DNA library into a clean 1.5 mL Eppendorf DNA
 1099 LoBind tube.
- 1100 31. Quantify 1 μL of adapter ligated and barcoded DNA using a Qubit fluorometer.
- 1101 32. Load 100 ng (51.36 fmol; considering 3kb) of final prepared library onto a flow cell following
- 1102 manufacturers recommendation.
- 1103 Note* The typical library size after this stage is around 3 kb. However, users can verify this by running the library
- 1104 on a gel or TapeStation for a few batches. Once the average expected library size is determined (sample or site-
- 1105 wise), there will be no need to repeat this for every batch of samples.
- 1106 For loading sequencing library or washing flow cells, follow the manufacturers recommended
- 1107 protocols.